These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33624623)

  • 1. Systemic therapies for hepatocellular carcinoma: the present and the future.
    Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G
    Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment options for hepatocellular carcinoma.
    Eugen K
    Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
    Rimassa L; Wörns MA
    Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
    Amaro CP; Tam VC
    Curr Oncol; 2020 Nov; 27(Suppl 3):S173-S180. PubMed ID: 33343211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
    Sun W; Cabrera R
    J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy of liver cancer.
    Demir T; Lee SS; Kaseb AO
    Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors.
    Piñero F; Silva M; Iavarone M
    World J Gastroenterol; 2020 Apr; 26(16):1888-1900. PubMed ID: 32390700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.